<DOC>
	<DOCNO>NCT00089102</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine irinotecan , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together irinotecan work treat patient locally advance unresectable metastatic kidney cancer .</brief_summary>
	<brief_title>Gemcitabine Irinotecan Treating Patients With Locally Advanced Unresectable Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response patient locally advance unresectable metastatic renal cell carcinoma treat gemcitabine irinotecan . Secondary - Determine duration response patient treat regimen . - Determine tolerance toxicity regimen patient . - Determine median progression-free survival patient treat regimen . OUTLINE : Patients receive gemcitabine IV 30 minute irinotecan IV 90 minute day 1 8 . Treatment repeat every 21 day 6-8 course absence disease progression unacceptable toxicity . Patients receive 2 additional course beyond best response . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 12-36 patient accrue study within 30 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Locally advance unresectable metastatic disease Unidimensionally measurable disease physical exam image study The following consider measurable disease : Bone disease Pleural peritoneal effusion CNS lesion Irradiated lesion unless disease progression document radiotherapy PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic ALT AST &lt; 3 time upper limit normal Bilirubin ≤ 2.0 mg/dL Renal Creatinine ≤ 2.0 mg/dL Gastrointestinal No active inflammatory bowel disease No significant bowel obstruction No chronic diarrhea Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation No mental incapacitation psychiatric illness would preclude give informed consent No active malignancy except nonmelanoma skin cancer No severe disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy At least 4 week since prior immunotherapy No concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy No concurrent hormone except steroid adrenal failure , hormone nondiseaserelated condition ( e.g. , insulin diabetes ) , intermittent dexamethasone antiemetic Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy No concurrent palliative radiotherapy Surgery Not specify Other No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>